Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04079738
Recruitment Status : Terminated (Funder requested termination due to halting internal development of TAK-659)
First Posted : September 6, 2019
Last Update Posted : March 31, 2022
Information provided by (Responsible Party):
H Scott Boswell, Big Ten Cancer Research Consortium

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : September 22, 2021
Actual Study Completion Date : February 23, 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 11, 2022
May 5, 2022 Submission with QC Comments
2 August 26, 2022
September 20, 2022 Submission with QC Comments
3 March 11, 2023
April 5, 2023 Submission with QC Comments